News
Endeavor
to Achieve Our Goals
Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys
September 16, 2021
© 2023 – Endeavor Biomedicines | Privacy Notice | Terms of Use
1st Patient Dosed in Trial of IPF Therapy Candidate Taladegib
September 24, 2021
Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
January 7, 2021
My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease
January 7, 2021
Endeavor BioMedicines Completes Enrollment in Phase 2a Clinical Trial of ENV-101 (Taladegib) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
/in news, Press ReleaseSeptember 6, 2023
Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)
/in news, Press ReleaseMay 31, 2022
Endeavor Doses First Patient in Phase 2 Oncology Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib)
/in news, Press ReleaseMay 25, 2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/in news, Press ReleaseFebruary 7, 2022
Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline
/in news, Press ReleaseFebruary 07, 2022
Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer
/in news, Press ReleaseSeptember 22, 2021
Endeavor Biomedicines Licenses Ulk1/2 Inhibitor Program From Salk Institute And Sanford Burnham Prebys To Broaden Its Precision Oncology Pipeline
/in news, Press ReleaseSeptember 16, 2021
Endeavor Biomedicines Launches With $62 Million Series A Financing And Mission To Reverse The Course Of Devastating Pulmonary Disease
/in news, Press ReleaseJanuary 7, 2021